^
Association details:
| Biomarker: | FGF19 expression |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ST6GAL1 is a novel serum biomarker for lenvatinib-susceptible FGF19-driven hepatocellular carcinoma
Published date:
12/07/2020
Excerpt:
...lenvatinib selectively eliminated FGF19-expressing tumors...FGF19 levels and lenvatinib susceptibility were correlated in HCC cell lines...FGF19 is a tumor biomarker of lenvatinib-susceptible HCC...
DOI:
10.1158/1078-0432.CCR-20-3382
